Last updated: Aug 20, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT05919238 | 1 | Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma | Unknown mechanism |
| NCT07175389 | 1, 2 | JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure | Unknown mechanism |
| NCT07214298 | 1, 2 | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | Complement C3 -- complement inhibitor (pegcetacoplan) combined with chemotherapy |
| NCT03454035 | 1 | Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | ERK + CDK4/6 -- kinase inhibition (ERK inhibitor + CDK4/6 inhibitor) |
| NCT01174121 | 2 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Tumor infiltrating lymphocytes (TILs) plus PD-1 blockade -- adoptive cell therapy plus immune checkpoint inhibitor |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 21 |
| Ruijin Hospital | 13 |
| Zhejiang University | 12 |
| Tianjin Medical University Cancer Institute and Hospital | 11 |
| West China Hospital | 8 |
Countries/regions with the most active trial sites for pancreatic cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Dec 16, 2026 | NCT07608627 | 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer | PSCA -- radiolabeled antibody fragment for imaging (radioconjugate) |
| Nov 1, 2026 | NCT07587827 | Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer | Neoantigens + CTLA-4 -- personalized DNA neoantigen vaccine combined with immune checkpoint blockade (anti-CTLA4 antibody) |
| Nov 2026 | NCT07738939 | IKS04 Regimen in Advanced Solid Tumors That Express CA242 | CA242 -- antibody-drug conjugate (ADC) |
| Oct 1, 2026 | NCT07645651 | Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer | CDK7 -- kinase inhibitor (small molecule) |
| Sep 30, 2026 | NCT07394205 | Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer | CLDN18.2 -- CAR-T cell therapy |
| Sep 8, 2026 | NCT07619521 | Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma | MEK1/2 + HER2 -- MEK inhibitor + antibody-drug conjugate (ADC) |
| Sep 2026 | NCT07698613 | EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer | EGFR -- antibody-photoabsorber conjugate (photoimmunotherapy) |
| Sep 2026 | NCT07756281 | First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer | RAS -- inhibitor (small molecule) |
You've seen the pancreatic cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.